Autologous Fat Grafting in the Treatment of Facial Scleroderma

Systemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of a...

Full description

Saved in:
Bibliographic Details
Main Authors: Mehdi Gheisari, Arman Ahmadzadeh, Nilofar Nobari, Behzad Iranmanesh, Nikoo Mozafari
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Dermatology Research and Practice
Online Access:http://dx.doi.org/10.1155/2018/6568016
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832550626152677376
author Mehdi Gheisari
Arman Ahmadzadeh
Nilofar Nobari
Behzad Iranmanesh
Nikoo Mozafari
author_facet Mehdi Gheisari
Arman Ahmadzadeh
Nilofar Nobari
Behzad Iranmanesh
Nikoo Mozafari
author_sort Mehdi Gheisari
collection DOAJ
description Systemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of autologous fat grafting in the face of patients with systemic sclerosis. We enrolled 16 SSc patients suffering from facial sclerosis and limited mouth opening capacity. Autologous fat injection ranging from 15 to 40 ml was administered per patient, based on their face morphology. The patients were evaluated at baseline and 3 months after fat injection. Evaluations included mouth opening capacity, mouth handicap in systemic sclerosis (MHISS), Rodnan skin sclerosis score, skin biophysical properties using a sensitive biometrologic device with the assessment of cutaneous resonance running time (CRRT), volumizing and aesthetic effects based on pre- and posttreatment photographs, possible side effects, and global patient satisfaction. Clinical assessment showed autologous fat transfer significantly improved mouth opening capacity and the MHISS and Rodnan score of patients with facial scleroderma (p value <.001). The aesthetic and/or functional results of fat injection were satisfying to about 80% of the patients. The changes in CRRT values were not significant. Our findings support the possible therapeutic role of autologous fat grafting in improving facial scleroderma both in aesthetic and in functional aspects. This trial is registered with IRCT20180209038677N1.
format Article
id doaj-art-6451893e703647c7a468e1ded8b0c737
institution Kabale University
issn 1687-6105
1687-6113
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Dermatology Research and Practice
spelling doaj-art-6451893e703647c7a468e1ded8b0c7372025-02-03T06:06:22ZengWileyDermatology Research and Practice1687-61051687-61132018-01-01201810.1155/2018/65680166568016Autologous Fat Grafting in the Treatment of Facial SclerodermaMehdi Gheisari0Arman Ahmadzadeh1Nilofar Nobari2Behzad Iranmanesh3Nikoo Mozafari4Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Rheumatology, Shahid Beheshti University of Medical Sciences, Tehran, IranSkin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranSkin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranSkin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranSystemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of autologous fat grafting in the face of patients with systemic sclerosis. We enrolled 16 SSc patients suffering from facial sclerosis and limited mouth opening capacity. Autologous fat injection ranging from 15 to 40 ml was administered per patient, based on their face morphology. The patients were evaluated at baseline and 3 months after fat injection. Evaluations included mouth opening capacity, mouth handicap in systemic sclerosis (MHISS), Rodnan skin sclerosis score, skin biophysical properties using a sensitive biometrologic device with the assessment of cutaneous resonance running time (CRRT), volumizing and aesthetic effects based on pre- and posttreatment photographs, possible side effects, and global patient satisfaction. Clinical assessment showed autologous fat transfer significantly improved mouth opening capacity and the MHISS and Rodnan score of patients with facial scleroderma (p value <.001). The aesthetic and/or functional results of fat injection were satisfying to about 80% of the patients. The changes in CRRT values were not significant. Our findings support the possible therapeutic role of autologous fat grafting in improving facial scleroderma both in aesthetic and in functional aspects. This trial is registered with IRCT20180209038677N1.http://dx.doi.org/10.1155/2018/6568016
spellingShingle Mehdi Gheisari
Arman Ahmadzadeh
Nilofar Nobari
Behzad Iranmanesh
Nikoo Mozafari
Autologous Fat Grafting in the Treatment of Facial Scleroderma
Dermatology Research and Practice
title Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_full Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_fullStr Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_full_unstemmed Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_short Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_sort autologous fat grafting in the treatment of facial scleroderma
url http://dx.doi.org/10.1155/2018/6568016
work_keys_str_mv AT mehdigheisari autologousfatgraftinginthetreatmentoffacialscleroderma
AT armanahmadzadeh autologousfatgraftinginthetreatmentoffacialscleroderma
AT nilofarnobari autologousfatgraftinginthetreatmentoffacialscleroderma
AT behzadiranmanesh autologousfatgraftinginthetreatmentoffacialscleroderma
AT nikoomozafari autologousfatgraftinginthetreatmentoffacialscleroderma